Wells Fargo analyst Mohit Bansal downgraded Vertex Pharmaceuticals (VRTX) to Equal Weight from Overweight with an unchanged price target of ...

Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $440.68, moving -0.72% from the previous trading session. This change lagged the S&P 500's daily gain of 0.92%. Meanwhile, the Dow ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

These real-time tables help economic and social statistics users to better analyze the impact and development of policy, to prepare forecasts, and to test econometric models ... American Product ...

In a report released today, Gena Wang from Barclays maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $418.00. The company’s shares closed ...

Mnwabisi Mbangata arrived at Vertex Pharmaceuticals almost two years ago with nearly a decade of experience — including five years at Eli Lilly in various roles — in bringing innovative therapies to ...

Ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) were provided by 23 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a concise ...

This innovative method combines deep learning with physics-based modeling to predict melt pool behavior faster ... to improve the efficiency of SLM processes, enable intelligent real-time process ...

Before locking in any college football bowl or CFP picks, be sure to see the latest college football predictions from SportsLine's proven model. The model simulates every FBS game 10,000 times.

Mivelsiran sodium is under clinical development by Alnylam Pharmaceuticals and currently in Phase II for Unspecified Central Nervous System Disorders. According to GlobalData, Phase II drugs for ...